Newsroom

LOUISVILLE, Ky.--(BUSINESS WIRE)--Sypris Solutions, Inc. (Nasdaq/GM: SYPR) today reported financial results for its second quarter ended July 5, 2026. HIGHLIGHTS   Orders increased 25% sequentially for the Company, driven by a 54% increase in bookings at Sypris Electronics for satellite and deep space programs, and subsea fiber-optic data network systems. Orders for energy products remained strong during the period, resulting in a 12% increase in bookings for the first half of 2026 when compare...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Global Equity Income UCITS ETF 17.08.2026 FGBL.LN IE00BYTH6121  781,889.00 USD  81,179,739.17  103.825  ...

PORTLAND, Ore.--(BUSINESS WIRE)--Nuuvia, the go-to youth banking platform designed specifically for community banks and credit unions, today announced the appointment of Marcell King as Chief Executive Officer. Under King’s leadership in the last 18 months as President and COO, the company more than doubled its customer base and contracted annual recurring revenue, expanded strategic channel partnerships and built a powerhouse leadership team to meet the rising demand for modern youth banking s...

NEW YORK--(BUSINESS WIRE)--Klarna Group plc [NYSE: KLAR], the everyday finance network, today announced planned transitions for its Chief Financial Officer and Chief Marketing Officer, to take effect in early 2027. Niclas Neglén, Chief Financial Officer for six years, and David Sandström, Chief Marketing Officer for nine years, will each remain in their roles and lead their organizations through the transition. "Niclas and David have helped shape what Klarna is. Niclas has built the finance org...

STUART, Fla.--(BUSINESS WIRE)--Stuart Therapeutics, Inc. (“Stuart”), a clinical-stage biopharmaceutical company developing first-in-class collagen-reparative therapeutics to treat eye diseases, today announced the appointment of David Jakeman as chief financial officer. Jakeman will lead the company's finance and accounting operations as Stuart advances its lead candidate, ST-100 for dry eye disease, through completion of its pending Phase 3b clinical trial and into preparations for commerciali...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 17.08.2026 FKUD IE00BD9N0445  121,463.00 GBP   3,801,785.28   31.300  ...

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust United Kingdom AlphaDEX UCITS ETF 17.08.2026 FKU IE00B8X9NZ57  181,700.00 GBP   8,217,118.49   45.224  ...

NEW YORK--(BUSINESS WIRE)--Regulatory News: Klarna Group plc [NYSE: KLAR], the everyday finance network, today reported second quarter 2026 results. GMV reached $36.6 billion (+18% YoY), revenue $1.042 billion (+27% YoY), transaction margin dollars $446 million (+42% YoY), and adjusted operating income $91 million (+214% YoY). "Over 120 million consumers now use Klarna, and each is using it for more of their everyday spend — revenue per active consumer grew 24%. That deepening engagement is why...

NEW YORK--(BUSINESS WIRE)--Klarna Group plc [NYSE: KLAR], the everyday finance network, today reported second quarter 2026 results. GMV reached $36.6 billion (+18% YoY), revenue $1.042 billion (+27% YoY), transaction margin dollars $446 million (+42% YoY), and adjusted operating income $91 million (+214% YoY). "Over 120 million consumers now use Klarna, and each is using it for more of their everyday spend — revenue per active consumer grew 24%. That deepening engagement is why transaction marg...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Brixton Biosciences (Brixton), a clinical-stage life sciences company focused on developing a nerve-selective biomaterial designed to provide targeted and durable relief from pain, today announced the appointment of three new members to its Board of Directors: founding CEO of Alnylam Pharmaceuticals and RNAi pioneer, John Maraganore, Ph.D.; CEO of Bausch + Lomb and biopharma deal-maker, Brent Saunders; and former General Manager, Philadelphia 76ers, Elton Bran...